NM_058195.4:c.193+5242G>A

Variant summary

Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1

The NM_058195.4(CDKN2A):​c.193+5242G>A variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.862 in 152,240 control chromosomes in the GnomAD database, including 56,651 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.

Frequency

Genomes: 𝑓 0.86 ( 56651 hom., cov: 33)

Consequence

CDKN2A
NM_058195.4 intron

Scores

2

Clinical Significance

Not reported in ClinVar

Conservation

PhyloP100: -0.627

Publications

19 publications found
Variant links:
Genes affected
CDKN2A (HGNC:1787): (cyclin dependent kinase inhibitor 2A) This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012]
CDKN2A Gene-Disease associations (from GenCC):
  • melanoma, cutaneous malignant, susceptibility to, 2
    Inheritance: AD Classification: DEFINITIVE Submitted by: G2P
  • melanoma-pancreatic cancer syndrome
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, ClinGen, Labcorp Genetics (formerly Invitae), Ambry Genetics
  • familial atypical multiple mole melanoma syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • melanoma and neural system tumor syndrome
    Inheritance: AD Classification: LIMITED Submitted by: Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -12 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.93).
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.956 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CDKN2ANM_058195.4 linkc.193+5242G>A intron_variant Intron 1 of 2 ENST00000579755.2 NP_478102.2
LOC124902130XR_007061436.1 linkn.3727G>A non_coding_transcript_exon_variant Exon 2 of 2
CDKN2ANM_001363763.2 linkc.-4+5924G>A intron_variant Intron 1 of 2 NP_001350692.1
CDKN2AXM_047422597.1 linkc.-4+5650G>A intron_variant Intron 1 of 2 XP_047278553.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CDKN2AENST00000579755.2 linkc.193+5242G>A intron_variant Intron 1 of 2 1 NM_058195.4 ENSP00000462950.1

Frequencies

GnomAD3 genomes
AF:
0.862
AC:
131172
AN:
152122
Hom.:
56618
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.830
Gnomad AMI
AF:
0.890
Gnomad AMR
AF:
0.888
Gnomad ASJ
AF:
0.834
Gnomad EAS
AF:
0.979
Gnomad SAS
AF:
0.938
Gnomad FIN
AF:
0.867
Gnomad MID
AF:
0.816
Gnomad NFE
AF:
0.862
Gnomad OTH
AF:
0.861
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome
AF:
0.862
AC:
131259
AN:
152240
Hom.:
56651
Cov.:
33
AF XY:
0.864
AC XY:
64312
AN XY:
74422
show subpopulations
African (AFR)
AF:
0.829
AC:
34437
AN:
41520
American (AMR)
AF:
0.888
AC:
13597
AN:
15304
Ashkenazi Jewish (ASJ)
AF:
0.834
AC:
2897
AN:
3472
East Asian (EAS)
AF:
0.979
AC:
5075
AN:
5186
South Asian (SAS)
AF:
0.938
AC:
4523
AN:
4822
European-Finnish (FIN)
AF:
0.867
AC:
9185
AN:
10598
Middle Eastern (MID)
AF:
0.816
AC:
240
AN:
294
European-Non Finnish (NFE)
AF:
0.863
AC:
58668
AN:
68018
Other (OTH)
AF:
0.863
AC:
1825
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.505
Heterozygous variant carriers
0
949
1897
2846
3794
4743
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
896
1792
2688
3584
4480
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.864
Hom.:
46306
Bravo
AF:
0.862
Asia WGS
AF:
0.939
AC:
3265
AN:
3478

ClinVar

Not reported in ClinVar

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.93
CADD
Benign
3.1
DANN
Benign
0.44
PhyloP100
-0.63
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.010
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs3731201; hg19: chr9-21988896; API